Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Segment Research Report 2024
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Beijing Yanjing Bizhi Information Consulting Co., Ltd. （XYZResearch）released the 《(Post-pandemic Era)-Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Severe Acute Respiratory Syndrome(SARS) Therapeutics industry at home and abroad, estimate the overall market scale of the Severe Acute Respiratory Syndrome(SARS) Therapeutics industry and the market share of major countries, Severe Acute Respiratory Syndrome(SARS) Therapeutics industry, and study and judge the downstream market demand of Severe Acute Respiratory Syndrome(SARS) Therapeutics through systematic research, Analyze the competition pattern of Severe Acute Respiratory Syndrome(SARS) Therapeutics, so as to help solve the pain points of various stakeholders in Severe Acute Respiratory Syndrome(SARS) Therapeutics industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Severe Acute Respiratory Syndrome(SARS) Therapeutics Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Severe Acute Respiratory Syndrome(SARS) Therapeutics Market?
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Major Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics Covered in XYZResearch report
CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others
Application Segments Covered in XYZResearch Market
Hospital
Clinic
Research Center
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Content
Table of Contents
Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market by Value
2.2.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue by Type
2.2.2 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market by Value (%)
2.3 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market by Production
2.3.1 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Production by Type
2.3.2 Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market by Production (%)
3. The Major Driver of Severe Acute Respiratory Syndrome(SARS) Therapeutics Industry
3.1 Historical & Forecast Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Demand
3.2 Largest Application for Severe Acute Respiratory Syndrome(SARS) Therapeutics (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Severe Acute Respiratory Syndrome(SARS) Therapeutics Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Severe Acute Respiratory Syndrome(SARS) Therapeutics Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Average Price Trend
12.1 Market Price for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in US (2018-2022)
12.2 Market Price for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Europe (2018-2022)
12.3 Market Price for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in China (2018-2022)
12.4 Market Price for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Japan (2018-2022)
12.5 Market Price for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in India (2018-2022)
12.6 Market Price for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Korea (2018-2022)
12.7 Market Price for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Severe Acute Respiratory Syndrome(SARS) Therapeutics Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Severe Acute Respiratory Syndrome(SARS) Therapeutics
14. Severe Acute Respiratory Syndrome(SARS) Therapeutics Competitive Landscape
14.1 CEL-SCI Corporation
14.1.1 CEL-SCI Corporation Company Profiles
14.1.2 CEL-SCI Corporation Product Introduction
14.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 GeneCure LLC
14.2.1 GeneCure LLC Company Profiles
14.2.2 GeneCure LLC Product Introduction
14.2.3 GeneCure LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Humabs BioMed SA
14.3.1 Humabs BioMed SA Company Profiles
14.3.2 Humabs BioMed SA Product Introduction
14.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Inovio Pharmaceuticals, Inc.
14.4.1 Inovio Pharmaceuticals, Inc. Company Profiles
14.4.2 Inovio Pharmaceuticals, Inc. Product Introduction
14.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Nanotherapeutics, Inc.
14.5.1 Nanotherapeutics, Inc. Company Profiles
14.5.2 Nanotherapeutics, Inc. Product Introduction
14.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Novavax, Inc.
14.6.1 Novavax, Inc. Company Profiles
14.6.2 Novavax, Inc. Product Introduction
14.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Phelix Therapeutics, LLC
14.7.1 Phelix Therapeutics, LLC Company Profiles
14.7.2 Phelix Therapeutics, LLC Product Introduction
14.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Protein Sciences Corporation
14.8.1 Protein Sciences Corporation Company Profiles
14.8.2 Protein Sciences Corporation Product Introduction
14.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
15. Conclusion
16. Methodology and Data Source
List of Figure
List of Tables and Figures
Figure 1. Total Demand by Application of Severe Acute Respiratory Syndrome(SARS) Therapeutics Industry (Volume)
Figure 2. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue in 2022
Figure 5. US Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Severe Acute Respiratory Syndrome(SARS) Therapeutics Revenue, by Type (Million USD) (2018-2028)
Table 4. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production, by Type (K Unit) (2018-2028)
Table 5. Severe Acute Respiratory Syndrome(SARS) Therapeutics Demand (K Unit) by Application (2018-2028)
Table 6. Severe Acute Respiratory Syndrome(SARS) Therapeutics Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Severe Acute Respiratory Syndrome(SARS) Therapeutics Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Severe Acute Respiratory Syndrome(SARS) Therapeutics in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. CEL-SCI Corporation Profiles
Table 61. CEL-SCI Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 62. CEL-SCI Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. CEL-SCI Corporation Strategic initiatives
Table 64. GeneCure LLC Profiles
Table 65. GeneCure LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 66. GeneCure LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. GeneCure LLC Strategic initiatives
Table 68. Humabs BioMed SA Profiles
Table 69. Humabs BioMed SA Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 70. Humabs BioMed SA Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Humabs BioMed SA Strategic initiatives
Table 72. Inovio Pharmaceuticals, Inc. Profiles
Table 73. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 74. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. Inovio Pharmaceuticals, Inc. Strategic initiatives
Table 76. Nanotherapeutics, Inc. Profiles
Table 77. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 78. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Nanotherapeutics, Inc. Strategic initiatives
Table 80. Novavax, Inc. Profiles
Table 81. Novavax, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 82. Novavax, Inc. Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. Novavax, Inc. Strategic initiatives
Table 84. Phelix Therapeutics, LLC Profiles
Table 85. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 86. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. Phelix Therapeutics, LLC Strategic initiatives
Table 88. Protein Sciences Corporation Profiles
Table 89. Protein Sciences Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Product Introduction
Table 90. Protein Sciences Corporation Severe Acute Respiratory Syndrome(SARS) Therapeutics Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Protein Sciences Corporation Strategic initiatives
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices